Brooks Laboratories Ltd
NSE:BROOKS

Watchlist Manager
Brooks Laboratories Ltd Logo
Brooks Laboratories Ltd
NSE:BROOKS
Watchlist
Price: 159.99 INR 2% Market Closed
Market Cap: 4.2B INR
Have any thoughts about
Brooks Laboratories Ltd?
Write Note

Brooks Laboratories Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Brooks Laboratories Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Brooks Laboratories Ltd
NSE:BROOKS
Selling, General & Administrative
-â‚ą108.4m
CAGR 3-Years
11%
CAGR 5-Years
3%
CAGR 10-Years
-14%
Divi's Laboratories Ltd
NSE:DIVISLAB
Selling, General & Administrative
-â‚ą11.2B
CAGR 3-Years
-9%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Selling, General & Administrative
-â‚ą191.6m
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Selling, General & Administrative
-â‚ą12.8B
CAGR 3-Years
-12%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Selling, General & Administrative
-â‚ą9.3B
CAGR 3-Years
-9%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Selling, General & Administrative
-â‚ą1.7B
CAGR 3-Years
-64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Brooks Laboratories Ltd
Glance View

Market Cap
4.2B INR
Industry
Life Sciences Tools & Services

Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

BROOKS Intrinsic Value
45.18 INR
Overvaluation 72%
Intrinsic Value
Price

See Also

What is Brooks Laboratories Ltd's Selling, General & Administrative?
Selling, General & Administrative
-108.4m INR

Based on the financial report for Jun 30, 2024, Brooks Laboratories Ltd's Selling, General & Administrative amounts to -108.4m INR.

What is Brooks Laboratories Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-14%

Over the last year, the Selling, General & Administrative growth was 25%. The average annual Selling, General & Administrative growth rates for Brooks Laboratories Ltd have been 11% over the past three years , 3% over the past five years , and -14% over the past ten years .

Back to Top